Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05WSP
|
|||
| Former ID |
DNC007885
|
|||
| Drug Name |
UK-396082
|
|||
| Synonyms |
UK-396082; UNII-2Q5861SUIG; UK-396,082; UK 396082; 2Q5861SUIG; CHEMBL398110; 400044-47-5; (2s)-5-Amino-2-[(1-Propyl-1h-Imidazol-4-Yl)methyl]pentanoic Acid; SCHEMBL3841442; GTPL8657; DTXSID70193074; BDBM50226610; DB12099; compound 21 [PMID: 17990866]; (2S)-5-amino-2-[(1-propylimidazol-4-yl)methyl]pentanoic acid; (S)-5-amino-2-((1-propyl-1H-imidazol-4-yl)methyl)pentanoic acid; (S)-2-(1-Propyl-1H-imidazole-4-ylmethyl)-5-aminopentanoic acid; 1H-Imidazole-4-propanoic acid, alpha-(3-aminopropyl)-1-propyl-, (alphaS)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Phase 1 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H21N3O2
|
|||
| Canonical SMILES |
CCCN1C=C(N=C1)CC(CCCN)C(=O)O
|
|||
| InChI |
1S/C12H21N3O2/c1-2-6-15-8-11(14-9-15)7-10(12(16)17)4-3-5-13/h8-10H,2-7,13H2,1H3,(H,16,17)/t10-/m0/s1
|
|||
| InChIKey |
OTDGPKRCQXSTPV-JTQLQIEISA-N
|
|||
| CAS Number |
CAS 400044-47-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carboxypeptidase B2 (CPB2) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pancreatic secretion | ||||
| Protein digestion and absorption | ||||
| Panther Pathway | Plasminogen activating cascade | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8657). | |||
| REF 2 | ClinicalTrials.gov (NCT01091532) A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.. U.S. National Institutes of Health. | |||
| REF 3 | Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.